Latest News & Announcements
-
05.26.2022 - European Commission Grants Conditional Approval of CARVYKTI® (Ciltacabtagene Autoleucel), Janssen’s First Cell Therapy, for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
In the pivotal clinical study CARTITUDE-1, 98 percent of patients with relapsed or refractory multiple myeloma responded to a one-time treatment with ciltacabtagene autoleucel and...
-
05.26.2022 - Johnson & Johnson to Provide Webcast Fireside Chat on Clinical Data to be Presented at the American Society of Clinical Oncology Annual Meeting and the Janssen Oncology Strategy and Portfolio
-
05.25.2022 - Janssen Presents Study Results Showing Clinical Efficacy for TREMFYA® (guselkumab) and Long-Term Safety Profile for STELARA® (ustekinumab) for Patients Living with Inflammatory Bowel Disease at Digestive Disease Week® 2022
New data show proportions of patients treated with TREMFYA who achieved clinical-biomarker response ranged from 47.5-66.7 percent across dose groups in the Phase 2 GALAXI 1 study...
Supplier Related Sites
Supplier Quality Expectations
In order to be considered as a potential supplier or to continue supplying Companies within the Johnson & Johnson Family of Companies, suppliers must meet a set of minimum expectations.